This animation created by Nature Reviews Cancer and Nature Reviews Immunology illustrates how tumour cells are sensed and destroyed by cells of the immune system and how tumours can evolve to evade immune-mediated elimination. Scientists are developing new immunotherapies that help the immune system to ‘fight back’ — the animation explains how these exciting new drugs work. Nature has full responsibility for all editorial content, including Nature Video content. This content is editorially independent of sponsors. See also: Nature Reviews Drug Discovery collection on Cancer immunotherapy: http://www.nature.com/nrd/collections/cancerimmuno Further reading: Focus on Tumour immunology & immunotherapy: http://www.nature.com/reviews/focus/tumourimmunology/index.html
Просмотров: 279924 nature video
Robert Rees answers questions about his job, including why he chooses to focus upon immunology and immunotherapy, and what changes he’s witnessed in cancer treatment over his career. http://ukcatalogue.oup.com/product/academic/medicine/9780199676866.do Tumor Immunology and Immunotherapy is edited by Dr Robert C. Rees, Director and Professor of Tumour Biology, The John van Geest Cancer Research Centre, Nottingham Trent University, UK. Robert is the head of a team researching prostate and breast cancer vaccine therapies. He has published extensively in the field of tumour immunology and has previously worked at The Universities of Sheffield and Nottingham and at The National Institutes of Health, Bethesda, USA. His laboratory has discovered several tumour antigens as immunotherapy targets and established many of these as biomarkers, associating with disease status. Robert has edited 3 other books on cancer immunity and he is an Editor for the journal Cancer Immunology and Immunotherapy, amongst other journals. © Oxford University Press
Просмотров: 1320 Oxford Academic (Oxford University Press)
Learn about the Society for Immunotherapy of Cancer (SITC)’s official open access, online, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC). JITC Clinical/Translational Cancer Immunotherapy Section Editor, James L. Gulley, MD, PhD, describes JITC’s tumor immunology and cancer immunotherapy focused content, editorial board, global scope and submission process. Visit https://jitc.biomedcentral.com/ to read the latest research from JITC.
Просмотров: 663 Society for Immunotherapy of Cancer
Oncologists are turning to a novel form of therapy to combat cancer: retraining or reengineering the immune system to quash tumor growth. In this seminar, hear from Harvard Medical School scientists and clinicians on the latest approaches that use the body’s own defenses to fight cancer. Speakers: - Arlene Sharpe, MD, PhD - Catherine J. Wu, MD - Jerome Ritz, MD - David F. McDermott, MD Like Harvard Medical School on Facebook: https://goo.gl/4dwXyZ Follow on Twitter: https://goo.gl/GbrmQM Follow on Instagram: https://goo.gl/s1w4up Follow on LinkedIn: https://goo.gl/04vRgY Website: https://hms.harvard.edu/
Просмотров: 12172 Harvard Medical School
Bavituximab ,An Experimental Immuno-Oncology Immunotherapy Against Cancer : Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor. These data detailing the immune-stimulatory mechanism of action of PS-targeting antibodies, such as the company's lead drug candidate bavituximab, are the subject of a manuscript published in the October 2013 issue of the American Association for Cancer Research (AACR) peer-reviewed journal, Cancer Immunology Research . Bavituximab is currently being evaluated in several solid tumor indications, including non-small cell lung cancer, breast cancer, liver cancer and rectal cancer with a trial in advanced melanoma anticipated to initiate in the near future. For more details please visit: www.tajpharma.com Copyright © 2004-2015 Taj Pharmaceuticals Limited. All rights reserved. This information - including product information - is intended only for residents of the United States. The products discussed herein may have different labeling in different countries. #Bavituximab #ImmunotherapyAgainstCancer
Просмотров: 1759 TAJ PHARMA
The concept of 'teaching' the immune system to recognize and destroy cancer cells is over a century old, but the development of immunotherapeutic strategies for cancer was slow for many decades. However, much has been learned about the immune system in the meantime, and with the recent approval of two new immunotherapeutic anticancer drugs and several drugs in late-stage development, a new era in anticancer immunotherapy is beginning. The video takes an audio-visual journey through the different approaches that are being investigated to harness the immune system to treat cancer. For more, check out the Nature Reviews Drug Discovery poster: http://www.nature.com/nrd/posters/cancerimmuno/index.html
Просмотров: 183120 nature video
Robert Rees answers questions on cancer stem cells and successful and potential treatments, including antibody therapy and vaccine based immunotherapy. http://ukcatalogue.oup.com/product/academic/medicine/9780199676866.do Tumor Immunology and Immunotherapy is edited by Dr Robert C. Rees, Director and Professor of Tumour Biology, The John van Geest Cancer Research Centre, Nottingham Trent University, UK. Robert is the head of a team researching prostate and breast cancer vaccine therapies. He has published extensively in the field of tumour immunology and has previously worked at The Universities of Sheffield and Nottingham and at The National Institutes of Health, Bethesda, USA. His laboratory has discovered several tumour antigens as immunotherapy targets and established many of these as biomarkers, associating with disease status. Robert has edited 3 other books on cancer immunity and he is an Editor for the journal Cancer Immunology and Immunotherapy, amongst other journals. © Oxford University Press
Просмотров: 5065 Oxford Academic (Oxford University Press)
Robert Rees answers questions on the importance of the immune system, and the role it plays in fighting cancer. http://ukcatalogue.oup.com/product/academic/medicine/9780199676866.do Tumor Immunology and Immunotherapy is edited by Dr Robert C. Rees, Director and Professor of Tumour Biology, The John van Geest Cancer Research Centre, Nottingham Trent University, UK. Robert is the head of a team researching prostate and breast cancer vaccine therapies. He has published extensively in the field of tumour immunology and has previously worked at The Universities of Sheffield and Nottingham and at The National Institutes of Health, Bethesda, USA. His laboratory has discovered several tumour antigens as immunotherapy targets and established many of these as biomarkers, associating with disease status. Robert has edited 3 other books on cancer immunity and he is an Editor for the journal Cancer Immunology and Immunotherapy, amongst other journals. © Oxford University Press
Просмотров: 401 Oxford Academic (Oxford University Press)
Video abstract of review paper "Nanocarrier - based immunotherapy in cancer management and research" published in the open access journal ImmunoTargets and Therapy by Singh MS and Bhaskar S. Abstract: Research in cancer immunotherapy has gained momentum in the last two decades, with many studies and clinical trials showing positive therapeutic outcomes. Immunotherapy can elicit not only a strong anticancer immune response which could even control metastases, but could also induce immunological memory, resulting in long-lasting protection in the prophylactic setting and protection against possible recurrence. Nanocarriers offer an attractive means for delivery of a multitude of therapeutic immunomodulators which are readily taken up by immune cells and can initiate a particular arm of an immunostimulatory cascade leading to tumor cell killing. This review focuses on recent advances in nanocarrier-mediated immunotherapy for the treatment of cancer. Both in vitro and in vivo studies as well as clinical progress are discussed in various sections. Description of the specific role of nanoparticle technology in immunotherapy highlights the way particles can be tailor-made in terms of size, structure, payload, and surface properties for active targeting to antigen-presenting cells and/or enhanced accumulation in the solid tumor. Read the review paper here: http://www.dovepress.com/nanocarrier-based-immunotherapy-in-cancer-management-and-research-peer-reviewed-article
Просмотров: 407 Dove Medical Press
Immunotherapy is the new big hope in the fight against cancer and in 2013 was voted ‘Breakthrough of the Year’ by Science magazine. Conventional treatment until now has generally involved a combination of surgery, chemotherapy and radiation. The new therapy is aimed at activating the body’s own defense system. If immune cells can identify a tumor as an enemy, there is a good chance of stopping the disease. Instead of trying to completely eliminate the tumor, the new concept focuses on improving the immune response to the cancer. Find more from Tomorrow Today at http://www.dw.de/program/tomorrow-today/s-3062-9798
Просмотров: 613 DW English
Video abstract of review paper "New modalities of cancer treatment for NSCLC: focus on immunotherapy" published in the open access journal Cancer Management and Research by Davies. Abstract: Recent advances in the understanding of immunology and antitumor immune responses have led to the development of new immunotherapies, including vaccination approaches and monoclonal antibodies that inhibit immune checkpoint pathways. These strategies have shown activity in melanoma and are now being tested in lung cancer. The antibody drugs targeting cytotoxic T-lymphocyte-associated antigen-4 and programmed cell death protein-1 immune checkpoint pathways work by restoring immune responses against cancer cells, and are associated with unconventional response patterns and immune-related adverse events as a result of their mechanism of action. As these new agents enter the clinic, nurses and other health care providers will require an understanding of the unique efficacy and safety profiles with immunotherapy to optimize potential patient benefits. This paper provides a review of the new immunotherapeutic agents in development for lung cancer, and strategies for managing patients on immunotherapy. Read the review paper here: http://www.dovepress.com/new-modalities-of-cancer-treatment-for-nsclc-focus-on-immunotherapy-peer-reviewed-article
Просмотров: 14269 Dove Medical Press
Understanding the Pathway article: http://ascopubs.org/doi/full/10.1200/JCO.2015.62.5244 The Journal of Clinical Oncology's "Understanding the Pathway" articles accompany an Original Report and describe the underlying pathway or biological process, explain its relevance to the original report, and highlight future therapeutic or investigational directions pertaining to the pathway in cancer.
Просмотров: 2771 ASCOcancer
Understanding the Pathway article: http://ascopubs.org/doi/full/10.1200/JCO.2016.69.6435 The Journal of Clinical Oncology's "Understanding the Pathway" articles accompany an Original Report and describe the underlying pathway or biological process, explain its relevance to the original report, and highlight future therapeutic or investigational directions pertaining to the pathway in cancer.
Просмотров: 276 ASCOcancer
Video abstract of review paper "Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy" published in the open access journal ImmunoTargets and Therapy by Drakes ML and Stiff PJ.
Просмотров: 145 Dove Medical Press
Rene Chee, a PhD biologist, was diagnosed with a rare and aggressive cancer. Chee recounts her evidence-driven journey to survive with immunotherapy, discusses the history and advances in immunotherapy and explains the science behind it. Chee is the author of “Curing Cancer with Immunotherapy”. This public lecture on cancer immunotherapy was given at Randolph-Macon College in February 2018.
Просмотров: 181 Curing Cancer with Immunotherapy
Understanding the Pathway article: http://ascopubs.org/doi/full/10.1200/JCO.2014.60.3449 The Journal of Clinical Oncology's "Understanding the Pathway" articles accompany an Original Report and describe the underlying pathway or biological process, explain its relevance to the original report, and highlight future therapeutic or investigational directions pertaining to the pathway in cancer.
Просмотров: 671 ASCOcancer
Cancer Survivor At Cancer Immunology Rubio Center
Просмотров: 112 CancerImmunology
Immunotherapy for cancer: what challenges still remain? If you enjoyed this video make sure to read the full article here to find out how we can overcome these challenges: www.oncology-central.com/2018/01/26/seven-challenges-immuno-oncology/ To gain free access to the latest oncology research, news and interviews with key opinion leaders - make sure to create your free Oncology Central account: www.oncology-central.com
Просмотров: 335 Oncology Central
LONDON — Two immunotherapy drugs when used together can shrink cancerous tumours by up to a third in some patients, a new British trial suggests. Combining two cancer drugs, ipilimumab and nivolumab, shrank cancerous tumors by a third in 58 percent of cases in a 945-patient medical trial published in the New England Journal of Medicine. The immune system has brakes in place to stop it from attacking the body's own tissue. Cancer uses these brakes to evade detection. The drugs used in the trial, ipilimumab and nivolumab, remove these brakes, helping the immune system deal with the cancer, according to the BBC. Response to the combined treatment varied among those patients trialled, with many reacting well, and others not seeing any benefit. Experts warned that combining the two treatments can cause severe side effects such as diarrhea and fatigue, as well as elevated liver enzymes and other symptoms. According to Bloomberg, the combined treatment would have an annual cost of more than $250,000 at current rates. It is hoped that the immunotherapies will lead to more effective cancer treatment in the future. The British-led trial was conducted by researchers from the Royal Marsden Hospital, London, South West Wales Cancer Institute and several other international institutions. The research was funded by Bristol-Myers Squibb, the company that manufactures the drugs being tested. ------------------------------------------------------------- Welcome to TomoNews, where we animate the most entertaining news on the internets. Come here for an animated look at viral headlines, US news, celebrity gossip, salacious scandals, dumb criminals and much more! Subscribe now for daily news animations that will knock your socks off. Visit our official website for all the latest, uncensored videos: http://us.tomonews.net Check out our Android app: http://bit.ly/1rddhCj Check out our iOS app: http://bit.ly/1gO3z1f Stay connected with us here: Facebook http://www.facebook.com/TomoNewsUS Twitter @tomonewsus http://www.twitter.com/TomoNewsUS Google+ http://plus.google.com/+TomoNewsUS/ Instagram @tomonewsus http://instagram.com/tomonewsus -~-~~-~~~-~~-~- Please watch: "Crying dog breaks the internet’s heart — but this sad dog story has a happy ending" https://www.youtube.com/watch?v=4prKTN9bYQc -~-~~-~~~-~~-~-
Просмотров: 12381 TomoNews US
Our Immunotherapy Patient Summit expert panel—Dr. Michael Postow, Dr. Robert Vonderheide, Dr. Dmitriy Zamarin, and Dr. Leena Gandhi (moderator)—delved into the current developments of immunotherapy for different types of cancer. cancerresearch.org/summit Meet the Experts Leena Gandhi, M.D., Ph.D. is the director of thoracic medical oncology at NYU’s Langone Medical Center and an associate professor of medicine at NYU’s Laura and Isaac Perlmutter Cancer Center. Dr. Gandhi’s work has mainly focused on lung cancer including using checkpoint inhibitors for patients with this type of cancer. She was a lead investigator in the crucial phase 1 of a clinical trial which explored the usefulness of using PD-L1 as a biomarker for patients receiving anti-PD-L1 checkpoint immunotherapy and continues to work on evaluations of potential biomarkers to refine use of immunotherapies. Our lung cancer immunotherapy webinar with Dr. Gandhi: http://bit.ly/2uO6Oo3 Michael Postow, M.D., is a physician at Memorial Sloan Kettering Cancer Center in the Melanoma and Immunotherapeutics Oncology Service. Dr. Postow completed his fellowship on clinical research in melanoma and immunotherapy at Memorial Sloan Kettering where he has been leading clinical trials involving immunotherapeutic agents. Additionally he is editor-in-chief for the journal “Clinical Skin Cancer” and serves on the editorial board of the “Journal for the Immunotherapy of Cancer.” Our Ask A Scientist about clinical trials series with Dr. Postow: http://bit.ly/ScientistPostow Robert Vonderheide, M.D., D.Phil. , director of the Abramson Cancer Center of the University of Pennsylvania Perelman School of Medicine, is an expert in immunobiology. His work explores how CD40, GM-CSF, PD-1, CTLA-4 and CD25 regulate the tumor environment and immune activity. He has also helped translate his research into novel immunotherapies that have been used to treat pancreatic cancer and melanoma patients. Our pancreatic cancer immunotherapy webinar with Dr. Vonderheide: http://bit.ly/2uKbOhD Dmitriy Zamarin, M.D., Ph.D., is a medical oncologist at Memorial Sloan Kettering Cancer Center who specializes on gynecologic cancers, including cervical, ovarian, and endometrial cancer. Dr. Zamarin’s research focuses on the novel ways to use the immune system to fight cancer, and he is involved in clinical trials that evaluate the use of novel immunotherapy drugs in cancer patients.
Просмотров: 1033 Cancer Research Institute
Nearly two decades ago, researcher James Allison found a way to use the body’s own immune system to kill malignant cells, a discovery that’s transforming cancer treatment and saving lives. Photo: Michael Stravato for The Wall Street Journal Subscribe to the WSJ channel here: http://bit.ly/14Q81Xy Visit the WSJ channel for more video: https://www.youtube.com/wsjdigitalnetwork More from the Wall Street Journal: Visit WSJ.com: http://online.wsj.com/home-page Follow WSJ on Facebook: http://www.facebook.com/wsjlive Follow WSJ on Google+: https://plus.google.com/+wsj/posts Follow WSJ on Twitter: https://twitter.com/WSJLive Follow WSJ on Instagram: http://instagram.com/wsj Follow WSJ on Pinterest: http://www.pinterest.com/wsj/ Follow WSJ on Tumblr: http://www.tumblr.com/tagged/wall-street-journal Don’t miss a WSJ video, subscribe here: http://bit.ly/14Q81Xy More from the Wall Street Journal: Visit WSJ.com: http://www.wsj.com Visit the WSJ Video Center: https://wsj.com/video On Facebook: https://www.facebook.com/pg/wsj/videos/ On Twitter: https://twitter.com/WSJ On Snapchat: https://on.wsj.com/2ratjSM
Просмотров: 18288 Wall Street Journal
On Friday, February 3, Roswell Park Cancer Institute announced the formation of Tactiva, a new cancer immunotherapy spinoff company. Learn more: https://goo.gl/V83dzz 0:00 Candace Johnson, PhD, President & CEO, Roswell Park 2:08 Kathy Hochul, Lieutenant Governor of New York 5:55 Kunle Odunsi, MD, PhD, Chief Medical Officer, Tactiva Therapeutics, LLC 14:01 Timothy Kennedy, New York State Senate 17:12 Candace Johnson, PhD, President & CEO, Roswell Park
Просмотров: 203 Roswell Park Comprehensive Cancer Center
Understanding the Pathway article: http://ascopubs.org/doi/full/10.1200/jco.2015.64.9970 The Journal of Clinical Oncology's "Understanding the Pathway" articles accompany an Original Report and describe the underlying pathway or biological process, explain its relevance to the original report, and highlight future therapeutic or investigational directions pertaining to the pathway in cancer.
Просмотров: 4044 ASCOcancer
Presented at: Microbiology & Immunology 2017: https://www.labroots.com/virtual-event/microbiology-2017 Presented by: Condie Carmack, PhD - Vice President of Precision Oncology, Vela Dx Speaker Biography: Condie Carmack, Ph.D. received his Ph.D. from the University of Utah in Experimental Pathology and did postdocs in Philadelphia, PA and San Diego, CA. in mouse genetics and molecular biology. He is the author or or co-author of 23 peer-reviewed journal. He wrote the first paper on quantitative PCR and the second paper on multiplex PCR. He served on the Science Advisory Board of Life Technologies Inc. as an expert in clinical PCR. He was co-author on the first paper creating human monoclonal antibodies from immunodeficient mice. Mice serve as the foundation for creation of the current immune checkpoint blockade antibodies such as ipilimumab and nivolumab. He also served as General Manager of the Cancer Genetics Lab at Baylor College of Medicine before joining Vela Diagnostics. Webinar: How Biomarker Testing Shapes Immunotherapy Abstract: The immune system is complex and dynamic, focused on defending the body from a host of pathogens ranging from viruses to cancer. A number of different mechanisms have evolved that help the body fight to control cancers and other disease. Unfortunately, sometimes these defenses break down and become compromised, enabling cancers to survive and grow within the host. Recent breakthroughs have shown that Immunotherapeutic approaches may be successful in helping the host's immune system battle cancer, providing the body with ways to protect itself from cancer. Key to making this work is an understanding of both who will benefit from the therapy and at what stage in disease progression the therapy will be effective. In our discussion we will look at how biomarker development can aide in addressing these challenges. We will cover: • Overview of Immunotherapies & their mechanisms of action • Biomarkers associated with Immunotherapies • Biomarker clinical testing • Immunotherapy adverse reactions & success stories Sponsored By: Vela Diagnostics Earn PACE/CME Credits: 1. Make sure you’re a registered member of LabRoots: https://www.labroots.com/virtual-event/microbiology-2017 2. Watch the webinar on YouTube above or on the LabRoots Website: https://www.labroots.com/virtual-event/microbiology-2017 3. Click Here to get your PACE: Credits expire on September 14, 2019 http://www.labroots.com/credit/pace-credits/2463/third-party LabRoots on Social: Facebook: https://www.facebook.com/LabRootsInc Twitter: https://twitter.com/LabRoots LinkedIn: https://www.linkedin.com/company/labroots Instagram: https://www.instagram.com/labrootsinc Pinterest: https://www.pinterest.com/labroots/ SnapChat: labroots_inc
Просмотров: 146 LabRoots
Dr. Lotze speaks about exciting developments in treating cancer with immunotherapy, T-Cells and Check-Point Inhibitors at a recent ACGT Scientific Symposium in New York City. Dr. Michael Lotze is a member of the Alliance for Cancer Gene Therapy (ACGT) Scientific Advisory Council and is also assistant vice chancellor for Sponsored Training Grants, Health Sciences, at the University of Pittsburgh and professor, Department of Surgery and Bioengineering, as well as vice chair, Surgery Research and director of Strategic Partnerships with the University of Pittsburgh Cancer Institute, and director of the Catalyst Program for the Clinical and Translational Science Institute. He is also the chief scientific officer with Lion Biotechnologies, Inc. Dr. Michael Lotze received his MD and PhD degrees from Northwestern University. Except for a two year period at GlaxoSmithKline, King of Prussia, PA, and a dozen years on the senior staff at the National Cancer Institute in Bethesda, Maryland, Dr. Lotze has done his work at the University of Pittsburgh. Dr. Lotze serves as associate editor of the Journal of Immunotherapy and Oncology. He initiated the first approved gene therapy protocols at the NIH and has treated over 100 patients on gene therapy protocols at the University of Pittsburgh. He is the co-inventor of 10 patents in dendritic cell vaccines and antigen discovery, and the author on over 500 scientific papers and chapters in basic and applied tumor immunology and cytokine biology. Currently, he is the leader in the area of exploring cancer as a disorder of cell death and is devising novel strategies to approach the disease in this context.
Просмотров: 397 ACGTFoundation
Board-certified in oncology and internal medicine, Dr. Urba specializes in clinical research and in the care of patients with melanoma. He has 30 years of experience in the development of immunotherapy. Dr. Urba earned his Ph.D. in immunology at the UCLA School of Medicine and his medical degree at the University of Miami. Dr. Urba completed his residency at Morristown Memorial Hospital in New Jersey, an affiliate of Columbia University College of Physicians and Surgeons in New York, N.Y. He was a clinical staff fellow in medical oncology at the National Cancer Institute (NCI), National Institutes of Health in Bethesda, Maryland. He was a senior staff fellow at the NCI Biological Response Modifiers Program and director of the NCI Clinical Services Program at the Frederick Cancer Research and Development Center in Frederick, Maryland. In 1993, Dr. Urba joined Providence Health & Services in Portland, to lead the Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center. Dr. Urba credits his mom, a 27-year breast cancer survivor, as the reason he went into cancer research. So when Providence set out to build the cancer center on the campus of Providence Portland Medical Center, Dr. Urba became involved in planning every detail. "I knew it had to pass the mom test," he says. "Would I want my mom to be cared for here? Would she have access to the newest treatment discoveries? Would she be treated with kindness and respect through every step of her care? The Providence Cancer Center passes the test. My mom finds that comforting. And so do I." Video introduction to Dr. Urba and Providence Cancer Center. Dr. Urba's strong commitment to research is evidenced in his activities. He is an affiliate investigator in the division of clinical research at the Fred Hutchinson Cancer Research Center and has been an invited speaker at numerous international scientific conferences. He has served on several oversight committees and advisory boards focused on cancer immunology and immunotherapy, including the melanoma, immunomolecular and genitourinary committees with Southwest Oncology Group; the cellular, tissue and gene therapies advisory committee of the Food and Drug Administration; and the NCI board of scientific counselors for clinical studies and epidemiology. Dr. Urba also serves on the editorial boards of the Journal of Immunotherapy, Journal of Translational Medicine, The Oncologist, and the Journal for ImmunoTherapy of Cancer.
Просмотров: 605 Providence Oregon
Led by Professor Simon Barry from the Hospital’s research team, in partnership researchers from the Cooperative Research Centre (CRC), our Foundation is raising funds in support of a new immunotherapy project called Car-T, targeting a treatment for solid cell cancerous tumours in children.
Просмотров: 66 WCH Foundation
GROUP NAME: Ammuno-therapy (group 25) Group members: - Gavin Huangfu - Ella Scacchia - Amy Stiklius - Pauline Deng We will use an animation to discuss immune editing, with emphasis on the role of the immune system in regulating tumour cells. We will be focusing on the three E’s - elimination, equilibrium and escape (and what can contribute to each of these stages). We will also highlight the type of immune cells that play a role in these processes and how they recognise tumour cells. References: Chung, D 2015., Immunology Cartoon Project. Available from: http://www.daisychung.com/#!immunology-cartoon-project-/c14po. 1 October 2015. Dunn, GP et al. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology. 3: 991-998. Dunn, GP Old, LJ & Schreiber, RD. 2004. The three Es of cancer immunoediting. Annual Review of Immunology. 22: 329-360 Mapara, MY. 2004. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. Journal of Clinical Oncology. 22: 1136-51. Smyth, MJ et al. 2005. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. Journal of Experimental Medicine. 202:583-88 Smyth, MJ et al. 2001. A fresh look at tumor immunosurveillance and immunotherapy. Nature Immunology. 2: 293-299.
Просмотров: 4393 PATH3309 Cancer Pathology
Originally published on 02 June, 2015 Sign up for a free trial of News Direct's animated news graphics at http://newsdirect.nma.com.tw/Reuters.aspx ------------------------------------------------------------------------------------------------ Two immunotherapy drugs when used together can shrink cancerous tumours by up to a third in some patients, a new British trial suggests. Combining two cancer drugs, ipilimumab and nivolumab, shrank cancerous tumors by a third in 58 percent of cases in a 945-patient medical trial published in the New England Journal of Medicine. The immune system has brakes in place to stop it from attacking the body’s own tissue. Cancer uses these brakes to evade detection. The drugs used in the trial, ipilimumab and nivolumab, remove these brakes, helping the immune system deal with the cancer, according to the BBC. Response to the combined treatment varied among those patients trialled, with many reacting well, and others not seeing any benefit. Experts warned that combining the two treatments can cause severe side effects such as diarrhea and fatigue, as well as elevated liver enzymes and other symptoms. According to Bloomberg, the combined treatment would have an annual cost of more than $250,000 at current rates. It is hoped that the immunotherapies will lead to more effective cancer treatment in the future. The British-led trial was conducted by researchers from the Royal Marsden Hospital, London, South West Wales Cancer Institute and several other international institutions. The research was funded by Bristol-Myers Squibb, the company that manufactures the drugs being tested. ------------------------------------------------------------------------------------------------ Next Media Animation’s News Direct service provides daily, high-quality, informative 3D animated news graphics that fill in for missing footage and help viewers understand breaking news stories or in-depth features on science, technology, and health. To subscribe to News Direct or for more info, please visit: http://newsdirect.nma.com.tw/Index.aspx
Просмотров: 1068 News Direct
www.rotarymadison.org February 28, 2018 New Research In Treating Childhood Cancer Dr. Ken DeSantes presented us with a hopeful account about the modern treatments for a dreadful, heartbreaking disease: childhood leukemia. Dr. DeSantes is Clinical Director of the Pediatric Hematology/Oncology program, and Director of the Hematopoietic Stem Cell Transplant program, at the American Family Children’s Hospital. So he knows of what he speaks.
Просмотров: 51 rotaryclubofmadison
Immunotherapy isn't new, but it's just beginning to be appreciated for its transformative powers of disease modification. This short video introduces immunotherapy as a solution for intractable disease and as a replacement for more noxious therapeutics. For more information, please visit www.beckman.com/home.
Просмотров: 98 Beckman Coulter Life Sciences
CRISPR genes are identified in immunotherapy against cancer, A team of researchers from the National Cancer Institute (INC) in the United States, coordinated by Nicholas P. Restifo, an immunology expert at this institution, has presented in the journal. Nature the findings of a large study that identifies more Of one hundred genes involved in the mechanism that facilitates the elimination of tumors through the use of the aforementioned T lymphocytes. For this, the genetic editing technology called CRISPR was used that has allowed them to "turn off" consecutively certain genes in cells of melanoma. We examined the genetic profiles of 11,000 individuals collected in the Atlas of the Cancer Genome. According to Shashank Patel, one of the INC biomedical sciences experts who participated in this work: The results show that in the success of this cancer treatment many genes play a key role, many more than we expected in a first moment. If the genes described in this study are validated in clinical trials, this type of treatment will be exceptionally advanced. According to Restifo: If we finally understand the mechanisms involved in resistance to immunotherapy we will be able to develop new tactics to combat the disease. In fact, in the future, this finding could accelerate the development of drugs that prevent tumor cells from using their escape mechanisms and thereby help patients experience a completely satisfactory response. At the origin of the CRISPR is the Spanish scientist Francis Mojica, who discovered in the DNA of some microbes in the salt flats of Santa Pola (Alicante) sequences that exercised defense against viruses.
Просмотров: 172 Aban Tech
For more information, please go to http://www.ocularmelanoma.org. This is Part 2 of the opening talk kicked off the 2012 Ocular Melanoma Foundation's Eye Am Not Along Patient Retreat. The talk was given by ocular melanoma experts, Dr. David Eschelman and Dr. Takami Sato. David Eschelman is an Associate Professor of Radiology at Jefferson Medical College and Associate Director of Interventional Radiology at Thomas Jefferson University Hospital in Philadelphia. After graduating from Jefferson Medical College, he completed his internship in general surgery and residency in diagnostic radiology at Boston University and Boston City Hospitals, followed by a fellowship in vascular and interventional radiology at Thomas Jefferson University Hospital. He is board certified by the American Board of Radiology, with a certificate of added qualifications in vascular and interventional radiology. He currently focuses on liverdirected therapies for patients with metastatic uveal melanoma, working closely with Takami Sato, M.D., Ph.D. and Carin Gonsalves, M.D. Takami Sato is a Professor of Medical Oncology at Jefferson Medical College of Thomas Jefferson University and at Thomas Jefferson University Hospitals in Philadelphia. Currently, he serves as the Director of the Metastatic Uveal Melanoma Program in the Department of Medical Oncology at Thomas Jefferson University Hospitals, the Co-leader of the Immunology Program at the Kimmel Cancer Center at Jefferson and as the Associate Director for International Affairs at the Kimmel Cancer Center at Jefferson. Dr. Sato has been named to Americas Top Oncologists (2007) and Best Doctors In America (2004-2008). Having led multiple clinical trials and been awarded numerous research grants, Dr. Sato now serves as Chief Editor to What's New in Oncology as well as on the editorial board of the Medical Science Monitorand as a reviewer for five scientific journals; International Journal of Cancer, Medical Science Monitor, Cancer Immunology and Immunotherapy, Cancer Research and Cancer. Dr. Sato received his medical degree at Jichi Medical School in Japan and went on to his post graduate training in Internal Medicine and Pediatrics at Oita Prefectural Mie Hospital. He completed his fellowship training in Pediatric Oncology at Jichi Medical School. Dr. Sato received his PhD in 1997 from Jichi Medical School in Japan.
Просмотров: 871 Ocular Melanoma Foundation
Dr. Hans Jacobs and Dr. Stefan Nierkens in a joint collaboration between the Departments of Tumour Immunology, Medical Oncology and Laboratory Medicine have recently published an article in top journal Lancet oncology with new insights into immunoltherapy of melanoma patients. Immunotherapy studies in patients with melanoma have reported success in the expansion of tumour-specific effector T cells in vivo, but even in the presence of substantial numbers of functional T cells circulating in the blood, favourable clinical outcomes are scarce. This failure to induce robust clinical responses might be related to tumour-induced immune evasion, rendering the host tolerant to melanoma antigens. Immunosuppression in the tumour microenvironment mediated by regulatory T cells (Treg) is a dominant mechanism of tumour immune escape and is a major hurdle for tumour immunotherapy. Accumulation of Treg in melanoma is frequently recorded and the ratio of CD8-positive T cells versus Treg in the tumour microenvironment is predictive for survival of patients with melanoma. Hence, depletion of Treg seems to be a promising strategy for the enhancement of melanoma-specific immunity. Indeed, murine studies have shown that Treg depletion greatly increases the efficacy of immunotherapy. But despite the success of some strategies in depletion of Treg in patients, overall clinical efficacy has been disappointing. The lack of Treg specificity of the Treg depleting strategies applied so far imply that well-designed studies into dosage, timing, and administration regimens with more specific agents are urgently needed. Depletion of functional Treg from the tumour microenvironment as part of multifaceted immunotherapeutic treatments is a major challenge to induce clinically relevant immune responses against melanomas. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol. 2012 Jan;13(1):e32-42. Photo: Hans Jacobs
Просмотров: 908 RIMLSinstitute
For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer.It's the biggest win so far for immunotherapy, which has had much of its success until now in less common cancers.In the study, Merck's Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone after nearly one year.The results are expected to quickly set a new standard of care for about 70,000 patients each year in the United States whose lung cancer has already spread by the time it's found.Another study found that an immunotherapy combo - the Bristol-Myers Squibb drugs Opdivo and Yervoy - worked better than chemo for delaying the time until cancer worsened in advanced lung cancer patients whose tumors have many gene flaws, as nearly half do.But the benefit lasted less than two months on average and it's too soon to know if the combo improves overall survival, as Keytruda did.All of these immune therapy treatments worked for only about half of patients, but that's far better than chemo has done in the past.'We're not nearly where we need to be yet,' said Dr. Roy Herbst, a Yale Cancer Center lung expert who had no role in the studies.Results were discussed Monday at an American Association for Cancer Research conference in Chicago and published by the New England Journal of Medicine. The studies were sponsored by the drugmakers, and many study leaders and Herbst consult for the companies.Keytruda, Yervoy and Opdivo are called checkpoint inhibitors. They remove a cloak that some cancer cells have that hides them from the immune system. The drugs are given through IVs and cost about $12,500 a month.Keytruda was approved last year as an initial treatment with chemo for the most common form of advanced lung cancer, but doctors have been leery to use it because that was based on a small study that did not show whether it prolongs life.The new study, led by Dr. Leena Gandhi of NYU's Perlmutter Cancer Center, gives that proof. In it, 616 patients were given chemo and some also received Keytruda. Those not given Keytruda were allowed to switch to it if their cancer worsened.After one year, 69 percent of people originally assigned to Keytruda were alive versus 49 percent of the others - a result that experts called remarkable considering that the second group's survival was improved because half of them wound up switching.How much it ultimately will extend life isn't known - more than half in the Keytruda group are still alive; median survival was just over 11 months for the others.The Keytruda combo also delayed the time until cancer worsened - an average of nine months versus five months for the chemo-only group.That's a big difference for such an advanced cancer, said Dr. Alice Shaw, a Massachusetts General Hospital lung cancer expert and one of the conference leaders. 'This is really a pivotal study ... a new standard of care,' sa AutoNews- Source: http://www.dailymail.co.uk/health/article-5621411/Immune-therapy-scores-big-win-against-lung-cancer-study.html?ITO=1490&ns_mchannel=rss&ns_campaign=1490
Просмотров: 68 US Sciencetech
Created and Narrated by Maria-Dolores Vazquez-Abad Recommended References: Immune response series by Maria-Dolores Vazquez-Abad, (2018 YouTube) Basic Immunology. 5th ed. 2015 European Respiratory Journal 2010 36: 1185 DOI: 10.1183/09031936.00028510; Cellular and Molecular Immunology, 7th edition. Front Immunol. 2014; 5: 520. doi: 10.3389/fimmu.2014.00520 Immunology Unit 1 Review and Project J. Immunol. Methods 289, 1-16. (2004) J. Pharm. Biomed. Anal. 48 (5), 1267-1281. (2008) EMEA guidelines on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. http://www.emea.europa.eu/pdfs/human/biosimilar/1432706en.pdf FDA Guidance for Industry, Assay Development for Immunogenicity Te sting for Therapeutic Proteins. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM192750.pdf Clin Chem. 51, 1983-1985. (2005) ASSAY and Drug Development Technologies. 5(5): 655-662. (2007). Bioanalysis 2 (4), 721-731(2010) Boris Gorovits: Bioanalytical Assays for Biotherapeutics 2017 ADME workshop; Fisher , T.S. et al.Cancer Immunology and Immunotherapy (2012) 61:1721-33 FDA Immunogenicity Assessment for Therapeutic Protein Products http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm EMA: Guideline on Immunogenicity assessment of therapeutic proteins 18 May 2017 EMEA/CHMP/BMWP/14327/2006 Rev 1 Glodsy et al Immunology 5th edition, 2003 J Allergy Clin Immunol 2005;115:584-91.
Просмотров: 81 maria-dolores vazquez-abad
The Global Cancer Immunotherapy Market was valued at $45 billion in 2016, and is estimated to reach $119 billion by 2023, growing at a CAGR of 15% during the forecast period. Full Report: https://kbvresearch.com/cancer-immunotherapy-market/
Просмотров: 8 KBV Research
Created and Narrated by Maria-Dolores Vazquez-Abad Recommended References: New Your Times, July 29, 1908 Cancer research, April 1946 Immunotherapy Approvals in 2015. Cancer Research Institute, Dec 2015 Journal for Immuno Therapy of Cancer 20175:94 https://doi.org/10.1186/s40425-017-0299-1 Tumor immunity and immunotherapy by Abul K. Abbas UCSF Fridman et al. Nat Rev Cancer 12:298, 2012 Immune response and Cytokine Pathways in Disease by Maria-Dolores Vazquez-Abad, (2018 YouTube). Dis Model Mech. 2012 July; 5(4): 423–433.; Microbes and Infection Volume 11, Issue 5, April 2009, Pages 625–630; Cellular Immunology Volume 275, Issues 1–2, January–February 2012, Pages 12–18; Blood September 1, 2006 vol. 108 no. 5 1571-1579 ; Inflamm Bowel Dis, 7: 43–50 (2001) ; Nature Cell Biology 7, 381 - 386 (2005) ; Immunology, 93: 257–263 (2001) ; Cytokine & Growth Factor Reviews Volume 15, Issue 1, February 2004, Pages 49–60; J Clin Invest. 2005;115(2):282–290.; Immunological Reviews, 102: 5–28; 1998; Immunity Volume 16, Issue 4, April 2002, Pages 559–569; The Journal of Immunology December 1, 1992 vol. 149 no. 11 3495-3502 ; Nature Reviews Immunology 8, 193-204 (March 2008) Coussens et al. Science 339:286, 2013 Ton N. Schumacher, and Robert D. Schreiber Science 2015;348:69-74 Antigen Presentation and T Lymphocyte Activation by Abul K. Abbas UCSF Abbas, Lichtman and Pillai. Basic Immunology, 5th edition, 2015 Elsevier Ribas A. N Engl J Med 2012;366:2517-2519 New developments in cancer immunotherapy by Adil Daud MBBS UCSF Blood 2015 125:4017-4023; doi: https://doi.org/10.1182/blood-2014-12-580068 N Engl J Med 2014; 371:1507-1517, October 16, 2014
Просмотров: 13 maria-dolores vazquez-abad
Cell Press Reviews: Cancer Therapeutics delivers a broad overview of latest developments in cancer research from leading voices, right to your fingertips. Select articles span some of the most compelling topics in cancer therapeutics including: - Genetic approaches for personal oncology - Targeting epigenetic dysregulation and protein interaction networks - Vaccines and antibodies in cancer immunotherapy - Tumor heterogeneity and chemotherapy resistance Tumor associated macrophages in anticancer treatment The book informs, inspires, and connects cancer researchers at all stages in their careers with timely insight into how cancer biology research is translated into clinical decisions and drug discovery, along with thought-provoking essays on broader issues such as the war on cancer and high failure rates in anti-cancer drug treatment. Cell Press Reviews: Cancer Therapeutics is part of the Cell Press Reviews book and e-book series. Buy your copy today and use code CPR20 at checkout to save 20%. http://ow.ly/wTDNV
Просмотров: 524 Cell Press Video
David Maloney, MD, PhD from the Fred Hutchinson Cancer Center, Seattle, WA provides an overview of the immunotherapy highlights from the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland. Dr Maloney describes the latest data presented on immunotherapy treatments in lymphoma, including CAR-T cell therapy and checkpoint inhibitor antibodies. Explaining the advances in the field of immunotherapy as well as the challenges, Dr Maloney discusses the approval of future novel treatments. With regards to the impact on patients, Dr Maloney assesses the risk to benefit ratio for patients receiving immunotherapy.
Просмотров: 193 VJHemOnc – Video Journal of Hematological Oncology
تابعنا على قنواتنا المختلفة ---------------------------------------------- http://www.egyptscholars.org ---------------------------------------------- https://twitter.com/EgyptScholars ---------------------------------------------- https://facebook.com/EgyptScholars ---------------------------------------------- شــاهد أيضا دوراتنا المتخصصة التــالية ---------------------------------------------- مشروع خطوات | دليلك للدراسة في الخارج http://goo.gl/HYO6V4 ---------------------------------------------- مشروع وعــــي | جديد التكنولوجيا بين يديك http://goo.gl/wbrnD0 ---------------------------------------------- مشروع مـمــكن | هندسـة من أجل المكـفـوفين http://goo.gl/TFrOh4 ---------------------------------------------- دورة متخصصة | أساسيات البحث العلــمي http://goo.gl/RTN3li ---------------------------------------------- دورة متخصصة | سـلســلــة الخـوارزميات http://goo.gl/IjuLkr ---------------------------------------------- دورة متخصصة | كورس إدارة المشروعات http://goo.gl/wpe6g6 ---------------------------------------------- دورة متخصصة | مجموعة مكافحة السرطان http://goo.gl/0U01VK ---------------------------------------------- دورة متخصصة | رحلة بحثية في علم المحاسبة http://goo.gl/ymMThB ---------------------------------------------- الدراسة في الخارج مجانا ,فوائد الدراسة في الخارج ,الدراسة فى الخارج ,سلبيات الدراسة في الخارج ,مكاتب الدراسة في الخارج ,كيفية الدراسة في الخارج ,الدراسه في بريطانيا ,مميزات الدراسة في الخارج ,الدراسه في استراليا ,دليل الدراسة في الخارج ,تكاليف الدراسة في الخارج ,صعوبات الدراسة في الخارج ,الدراسه في انجلترا ,الدراسه في اكرانيا ,الدراسة في الجامعات ,التعليم فى الخارج ,منح دراسية في كندا ,الدراسة بالخارج مجانا ,دليل الدراسة بالخارج ,دراسة الماجستير في بريطانيا ,دراسة الماجستير في امريكا ,دراسة الماجستير في السعودية ,دراسة الماجستير في مصر ,دراسة الماجستير في الاردن ,دراسة الماجستير في كندا ,دراسة الماجستير في الهند ,دراسة الماجستير في تركيا ,دراسة الماجستير في المانيا ,دراسة الماجستير في الامارات ,دراسة الماجستير في الكويت ,تكلفة دراسة الماجستير في بريطانيا ,دراسة الماجستير في استراليا ,تكلفة دراسة الماجستير في امريكا ,مدة دراسة الماجستير في امريكا ,دراسة الماجستير في اوكرانيا ,دراسة الماجستير في قطر ,دراسة الماجستير في العراق ,دراسة الماجستير في جامعة الملك سعود ,دراسة الماجستير في البحرين ,الماجستير في ماليزيا ,دراسة الماجستير في روسيا ,دراسة الماجستير في السويد ,متطلبات دراسة الماجستير في امريكا ,دراسة الماجستير في تونس ,دراسة الماجستير في ايرلندا ,كيف دراسة الماجستير في امريكا ,دراسة الماجستير في ايطاليا ,مدة الماجستير في امريكا ,دراسة الماجستير في هولندا ,كيفية دراسة الماجستير ,مدة دراسة الماجستير ,كيف دراسة الماجستير ,دراسة الماجستير بالانتساب ,تقديم دراسة الماجستير ,دراسة الماجستير في ماليزيا ,طرائق البحث العلمي ,كيفية البحث العلمي ,عرف البحث العلمي ,خطه البحث ,اساسيات البحث ,رياده الاعمال ,تعريف ريادة الأعمال ,مركز ريادة الأعمال ,ريادة الأعمال الاجتماعية ,برنامج ريادة الاعمال ,بحث عن ريادة الاعمال ,مفهوم ريادة الأعمال ,مركز الأعمال ,عالم الاعمال والتقنية ,دورات في الاداره ,دورات في المحاسبة
Просмотров: 1791 Egypt Scholars Inc.
James Allison of the MD Anderson Cancer Center has made key discoveries on the regulation of T cell activation and modulation, including identification and characterization of the T cell antigen receptor and the T cell coreceptors CD28 and cytotoxic T lymphocyte antigen-4 (CTLA-4). He was awarded the 2015 Lasker~DeBakey Clinical Medical Research Award in honor of his discovery and subsequent development of CTLA-4–targeted monoclonal antibody therapy to unleash the immune response to cancer. In an interview with JCI Editor at Large Ushma Neill, Allison discusses his decision to pursue a PhD instead of an MD and his early experiences in applying biochemical techniques to immunological questions. Additionally, Allison talks about the process of moving anti-CTLA-4 therapy into the clinic.
Просмотров: 3798 Journal of Clinical Investigation
Samuel Wagner, President and CEO of Batu Biologics, discusses the significance of the tumor endothelium as the first immunological barrier masking the tumor from detection and destruction by the host's immune system. Work Cited: Motz et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014 May 4 About Batu Biologics: Batu Biologics is a preclinical biopharmaceutical company focusing on developing and commercializing allogeneic cell therapies in the area of immune modulation. Our products are centered around the idea of creating or breaking immune tolerance. The company is currently in the preclinical stages of drug development for its two flagship products: Immstem™ and Vallovax™. Batu Biologics has filed two provisional patents in the field of cancer immunotherapy and plans to significantly expand its IP in 2014. Recently, Batu Biologics published in the peer reviewed literature with Dr. Francesco Marincola, President of the Society for Immunotherapy of Cancer, as well as several other internationally-renowned immunotherapists, a novel method of decreasing toxicity of immunotherapy http://www.translational-medicine.com/content/pdf/1479-5876-12-127.pdf www.batubiologics.com
Просмотров: 713 Batu Biologics
Immunotherapy has been hailed as a ‘breakthrough’ in the treatment of cancer. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, Clinical Professor of Genitourinary Oncology of Barts Cancer Institute, Queen Mary University of London, London, UK, reviews the role of immunotherapy, an approach that stimulates the body’s own anticancer mechanisms, for the treatment of patients with kidney cancer.
Просмотров: 40 Patient Power Europe
The study has been published in the Journal of Allergy and Clinical Immunology. http://www.jacionline.org/article/S0091-6749(16)30969-1/abstract FOLLOW US ON FACEBOOK www.facebook.com/tabkhat twitter www.twitter.com/miamolosiva source: http://www.sciencealert.com/new-immunotherapy-technique-could-mean-a-cure-for-food-allergies
Просмотров: 2386 Article-TUBE2
GcMAF eradicates cancer; cells seen via microscopes and time lapse photography. This is a world wide first, and a scientific research paper named "Multifaceted immunotherapeutic effects of GcMAF on human breast cancer cells" peer reviewed, and published by us in the January 2013 Immunology Conference in San Diego. Human MCF7 breast cancer cells are shown both in a corrugated layer on the surface below and as irregular "fingers" above. Macrophages are small round circles added at the bottom left. They do nothing until the First Immune GcMAF is added. Time lapse photography over 60 hours shows the cancer monolayer below first changing from corrugated to smooth from the bottom left as the cancer is destroyed; then the cancer "fingers" are also eaten and destroyed by the macrophages. This is part of the assays performed on batches of our GcMAF, and are carried out in First Immune (gcmaf.se) laboratories as part of our everyday production. This confirms the research paper "Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells," published in the journal Anticancer Research 2012 Jan;32(1):45-52, in which they also kindly used our First Immune GcMAF for their experiments.
Просмотров: 2138 First Immune
Foodie Body - Targeted Immunotherapy. By using the body’s own immune system, it is possible not only to specifically target and eliminate cancer cells while leaving healthy cells unharmed but also to elicit long-term protective response. It is well established that the immune system can be utilized in the epic battle against cancer. Immune cells possess a unique ability to distinguish between cancer and normal cells with reliance on specific expression of cell-surface tumor-associated antigens (TAA) or self-antigens. Due to this ability, immune cells can act as “killing bullets” that are able to specifically eliminate tumors cells. Sulforaphane and Its effects on cancer, mortality, aging, brain and behavior, heart disease & more.
Просмотров: 1603 Gavin Simpson